Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review.

Aly-Khan A LalaniDaniel Y C HengNaveen S BasappaLori WoodNayyer IqbalDeanna McLeodDenis SoulièresChristian Kollmannsberger

Published in: Therapeutic advances in medical oncology (2022)

Phase III first-line trials of ICI combinations showed survival benefits compared with a control arm of sunitinib. Global access to these combinations should be made available to patients with advanced RCC.

Keyphrases

combination therapy
phase iii
renal cell carcinoma
open label
papillary thyroid
clinical trial
phase ii
double blind
placebo controlled
squamous cell
single cell
metastatic renal cell carcinoma
lymph node metastasis
free survival
randomized controlled trial